Recerca
Àrea 5
Hemoteràpia-Hemostàsia
Factor d'impacte: mitjana: 5.73, total: 263.64
Articles de l'any 2010
Original
-
Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group
Cervantes F, Lopez-Garrido P, Montero MI, Jonte F, Martinez J, Hernandez-Boluda JC, Calbacho M, Sureda A, Perez-Rus G, Nieto JB, Perez-Lopez C, Roman-Gomez J, Gonzalez M, Pereira A, Colomer D
HAEMATOL-HEMATOL J. 2010; 95: 1317-1324. IF: 6.416 -
Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem-cell transplantation
DeLarrea CF, Martinez C, Gaya A, Lopez-Guillermo A, Rovira M, Fernandez-Aviles F, Lozano M, Bosch F, Esteve J, Nomdedeu B, Montserrat E, Carreras E
ANN ONCOL. 2010; 21: 1211-1216. IF: 5.647 -
Association study between polymorphims in GAS6-TAM genes and carotid atherosclerosis
Hurtado B, Abasolo N, Munoz X, Garcia N, Benavente Y, Rubio F, DeFrutos PG, Krupinski J, Sala N
THROMB HAEMOSTASIS. 2010; 104: 592-598. IF: 4.451 -
Polymorphisms in platelet glycoproteins Ia and IIIa are associated with arterial thrombosis and carotid atherosclerosis in type 2 diabetes
Pellitero S, Reverter JL, Tassies D, Pizarro E, Monteagudo J, Salinas I, Aguilera E, Sanmarti A, Reverter JC
THROMB HAEMOSTASIS. 2010; 103: 630-637. IF: 4.451 -
Hormonal responses to the 5-HT1A agonist buspirone in remitted endogenous depressive patients after long-term imipramine treatment
Gomez-Gil E, Navines R, DeOsaba MJM, Diaz-Ricart M, Escolar G, Salamero M, Martin-Santos R, Galan A, Gasto C
PSYCHONEUROENDOCRINO. 2010; 35: 481-489. IF: 4.194 -
Thrombin activatable fibrinolysis inhibitor and clot lysis time in women with recurrent miscarriage associated with the antiphospholipid syndrome
Martinez-Zamora MA, Creus M, Tassies D, Bove A, Reverter JC, Carmona F, Balasch J
FERTIL STERIL. 2010; 94: 2437-2440. IF: 3.97 -
Effects of Adipose Tissue-Derived Stem Cell Therapy After Myocardial Infarction: Impact of the Route of Administration
Rigol M, Solanes N, Farre J, Roura S, Roque M, Berruezo A, Bellera N, Novensa L, Beng DT, Prat-Vidal C, Huzman MA, Batlle M, Hoefsloot M, Sitges M, Ramirez J, Dantas AP, Merino A, Sanz G, Brugada J, Bayes-Genis A, Heras M
J CARD FAIL. 2010; 16: 357-366. IF: 3.254 -
Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: Role of the Conditioning Regimen and the Type of Transplantation
Palomo M, Diaz-Ricart M, Carbo C, Rovira M, Fernandez-Aviles F, Martine C, Ghita G, Escolar G, Carreras E
BIOL BLOOD MARROW TR. 2010; 16: 985-993. IF: 3.149 -
Engraftment syndrome after auto-SCT: analysis of diagnostic criteria and risk factors in a large series from a single center
Carreras E, Fernandez-Aviles F, Silva L, Guerrero M, DeLarrea CF, Martinez C, Rosinol L, Lozano M, Marin P, Rovira M
BONE MARROW TRANSPL. 2010; 45: 1417-1422. IF: 2.998 -
Practices associated with ABO-incompatible platelet transfusions: a BEST Collaborative international survey
Lozano M, Heddle N, Williamson LM, Wang G, Aubuchon JP, Dumont LJ
TRANSFUSION. 2010; 5: 1743-1748. IF: 2.982 -
Allogeneic blood transfusion does not increase the risk of wound infection in total knee arthroplasty
Basora M, Pereira A, Soriano A, Martinez-Pastor JC, Sanchez-Etayo G, Tio M, Salazar F
VOX SANG. 2010; 98: 124-129. IF: 2.585 -
Problems with irradiators
Tadokoro K, Reesink HW, Panzer S, Chabanel A, Santailler G, Guerin T, Socquet D, David B, Labrune JL, Lin CK, Tsoi WC, Letowska M, Antoniewicz-Papis J, Naniewicz J, Dudziak K, Lachert E, Lozano M, Schneider K, Snyder EL, Champion MH
VOX SANG. 2010; 98: 78-84. IF: 2.585 -
Red-blood-cell alloimmunization and female sex predict the presence of HLA antibodies in patients undergoing liver transplant
Sanz C, Ghita G, Franquet C, Martinez I, Pereira A
VOX SANG. 2010; 99: 261-266. IF: 2.585 -
Pathogen inactivation of platelet concentrates
Reesink HW, Panzer S, Mcquilten ZK, Wood EM, Marks C, Wendel S, Trigo F, Biagini S, Olyntho S, Devine DV, Mumford I, Cazenave JP, Rasongles P, Garraud O, Richard P, Schooneman F, Vezon G, AlRadwan R, Brand A, Hervig T, Castro E, Lozano M, Navarro L, Puig L, Almazan C, Maclennan S, Cardigan R, Franklin IM, Prowse C
VOX SANG. 2010; 99: 85-95. IF: 2.585 -
Clot lysis time and thrombin activatable fibrinolysis inhibitor in severe preeclampsia with or without associated antiphospholipid antibodies
Martinez-Zamora MA, Tassies D, Carmona F, Espinosa G, Cerverac R, Reverter JC, Balasch J
J REPROD IMMUNOL. 2010; 86: 133-140. IF: 2.519 -
Preanalytical treatment of EDTA-anticoagulated blood to ensure stabilization of the mean platelet volume and component measured with the ADVIA counters
Diaz-Ricart M, Brunso L, Pino M, Navalon F, Jou JM, Heras M, White JG, Escolar G
THROMB RES. 2010; 126: 0-0. IF: 2.406 -
Genotypes Coding for Low Serum Levels of Mannose-Binding Lectin Are Underrepresented among Individuals Suffering from Noninfectious Systemic Inflammatory Response Syndrome
Smithson A, Perello R, Aibar J, Espinosa G, Tassies D, Freire C, Castro P, Suarez B, Lozano F, Nicolas JM
CLIN VACCINE IMMUNOL. 2010; 17: 447-453. IF: 2.373 -
The secretory mechanisms in equine platelets are independent of cytoskeletal polymerization and occur through membrane fusion
Brunso L, Segura D, Monreal L, Escolar G, White JG, Diaz-Ricart M
PLATELETS. 2010; 21: 658-666. IF: 2.272 -
Growth Arrest-Specific Protein 6 Is Hepatoprotective Against Murine Ischemia/Reperfusion Injury
Llacuna L, Barcena C, Bellido-Martin L, Fernandez L, Stefanovic M, Mari M, Garcia-Ruiz C, Fernandez-Checa JC, DeFrutos PG, Morales A
HEPATOLOGY. 2010; 52: 1371-1379. IF: 10.84 -
Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia
Alvarez-Larran A, Cervantes F, Pereira A, Arellano-Rodrigo E, Perez-Andreu V, Hernandez-Boluda JC, Ayats R, Salvador C, Muntanola A, Bellosillo B, Vicente V, Hernandez-Nieto L, Burgaleta C, Xicoy B, Besses C
BLOOD. 2010; 116: 1205-1210. IF: 10.555 -
Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance
Moreno C, Hodgson K, Ferrer G, Elena M, Filella X, Pereira A, Baumann T, Montserrat E
BLOOD. 2010; 116: 4771-4776. IF: 10.555 -
ABO incompatible living donor kidney transplantation: a dream come true. Experience of Hospital Clinic of Barcelona
Oppenheimer F, Revuelta I, Serra N, Lozano M, Gutierrez-Dalmau A, Esforzado N, Cofan F, Ricart MJ, Torregrosa JV, Crespo M, Paredes D, Martorell J, Alcaraz A, Campistol JM
NEFROLOGIA. 2010; 30: 54-63. IF: 0.533
Editorials
-
GAS6 in systemic inflammatory diseases: with and without infection
Hurtado B, DeFrutos PG
CRIT CARE. 2010; 14: 0-0. IF: 4.931 -
Erythrophagocytosis in cold agglutinin disease
Beya MD, Pereira A, Merino A
TRANSFUSION. 2010; 50: 2310-2310. IF: 2.982
Multicèntrics
-
A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology
Cazenave JP, Follea G, Bardiaux L, Boiron JM, Lafeuillade B, Debost M, Lioure B, Harousseau JL, Tabrizi R, Cahn JY, Michallet M, Ambruso D, Schots R, Tissot JD, Sensebe L, Kondo T, Mccullough J, Rebulla P, Escolar G, Mintz P, Heddle NM, Goodrich RP, Bruhwyler J, Le C, Cook RJ, Stouch B
TRANSFUSION. 2010; 50: 2362-2375. IF: 2.982